Japan’s Dainippon Sumitomo Pharma said that it will buy U.S.-based Boston Biomedical for $200 million to expand its cancer treatment business and extend its global reach.
Japanese company to buy U.S. bio-venture
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.